More stories
Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and the Fight for...
PODCAST INSERT In this episode, Joe Moore is joined by Kat Murti, Executive Director of Students for Sensible Drug Policy (SSDP), the largest youth-led...
Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression
This morning, Reunion Neuroscience shared positive topline data from its Phase 2 trial of RE104 in postpartum depression (PPD), a study that saw 84...
Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection
The Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) produces 5-MeO-DMT in its skin. Demand for that molecule now pressures a fragile animal. Retreats...
One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect
Last August, Lykos Therapeutics announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) to its new drug...
Harry Pack NFT – Last Call
A few months ago, artist Harry Pack had all of his art, and tools stolen while traveling the United States from the UK. We...
From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research
One of the things that made the recent Neurobiology of Psychedelics Gordon Research Conference (GRC) special was that it provided a venue for junior...
Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness
Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness is an eight-week live online course designed for therapists, wellness practitioners, and psychedelic...
Essentials of Psychedelic Therapy & Integration
Navigating Psychedelics: Essentials of Psychedelic Therapy & Integration is a 9-week online training designed for clinicians, coaches, and wellness practitioners seeking a comprehensive foundation...
Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease...
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as...
GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin
More people than ever are taking GLP-1 receptor agonists—drugs like Ozempic (semaglutide), Wegovy, and Mounjaro. These medications, originally developed for type 2 diabetes, are...
Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism...
Ketamine-assisted therapy (KAT) shows remarkable promise as a breakthrough psychiatric treatment for severe alcohol addiction, but recreational use of the dissociative is spiralling out...
